| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Stevanato Group S.p.A.$18.65
+0.19 (+1.03%)
Market Cap
4.92 B
EPS
0.60
P/E Ratio
29.98 $
Value Trade
8.78 M
1.92 %
Week
16.49 %
1 Month
11.45 %
3 Month
-15.13 %
6 Month
8.17 %
5 Year
8.17 %
All Time
Cash Data
Cash Position
153.39 M
Monthly Burn
26.35 M
Runway
4.88 mo
Overview
Volume
22.64 K
52 Week Range
12.89 - 28
% held by Insiders
81.79 %
% held by Institutions
17.27 %
Enterprise Value
5.30 B
Total Shares
49.70 M
Short %
2.07 %
Float Shares
48.95 M
Company Description
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end p Read More+
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV 8.57 M (138.97%) | Shares Owned 332.91 K (89.5%) | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
STVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STVN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STVN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
STVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 54 | 47 | 1.15 | 127 | 318 | 2.5 | 19.96% | 1.17% | 1.68% | 6.11% | 1.09% | 1.85% |
| 2026-06-18 | 54 | 47 | 1.15 | 127 | 318 | 2.5 | 19.96% | 1.17% | 1.68% | 6.11% | 1.09% | 1.85% |
| 2026-06-18 | 54 | 47 | 1.15 | 127 | 318 | 2.5 | 19.96% | 1.17% | 1.68% | 6.11% | 1.09% | 1.85% |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| - | - | 0 | 7.5 | - | - | 0 |
| - | - | 0 | 7.5 | - | - | 0 |
| - | - | 0 | 7.5 | - | - | 0 |
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Stevanato Group S.p.A. (STVN) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How STVN ranks across every disease it competes in No competitive intelligence available for STVN.